Princeton University Department of Chemistry

Inexpensive Catalysts and Syzygy Plasmonics Photoreactors Open the Door for Broader Hydrogen Adoption

Retrieved on: 
Tuesday, December 6, 2022
Photon, Chemical industry, Electricity, LED, Ruthenium, Aluminium, Glass, Research, Ammonia, Chemical engineering, Rice, Energy, Laboratory, Rice University, Multimedia, Environment, Princeton University Department of Chemistry, Hydrogen, Metal, Princeton University, Greenhouse, Lithium, Coal, Science, Syzygy

HOUSTON, Dec. 6, 2022 /PRNewswire/ -- Scientists from Syzygy Plasmonics have engineered a new kind of reactor designed to work with earth-abundant, light-activated catalysts created by a joint team from Rice University's Laboratory for Nanophotonics, Syzygy Plasmonics, and Princeton University's Andlinger Center for Energy and the Environment. The reactors use light instead of heat from combustion to power chemical reactions and can produce clean-burning hydrogen fuel from ammonia.

Key Points: 
  • The reactors use light instead of heat from combustion to power chemical reactions and can produce clean-burning hydrogen fuel from ammonia.
  • As reported by Rice, the inexpensive copper-iron catalysts tested in their labs maintained efficiency at a scale 500 times larger when tested in a Syzygy photoreactor.
  • With the recent closing of our Series-C fundraise , we are taking Syzygy reactors to market to produce zero-emissions hydrogen from ammonia."
  • Combining Syzygy reactors and inexpensive catalysts has the potential to reduce production costs of lower-carbon hydrogen to the point where importing ammonia as an energy carrier is a competitive option.

Princeton NuEnergy (PNE) Receives Prestigious Entrepreneurship Award

Retrieved on: 
Friday, October 14, 2022
Efficiency, MS, Princeton University Department of Chemistry, Organization, Recycling, Research, Technology, University, EVS, LIB, Associate, PNE, LPAS, Entrepreneurship, CO2, Lithium, Princeton University

BORDENTOWN, N.J., Oct. 14, 2022 /PRNewswire/ -- Three founding researchers of Princeton NuEnergy , Dr. Xiaofang Wang, Jerry Xiang, MS, and Dr. Chao Yan have been selected as the recipients of Princeton University's prestigious 2022 Tiger Entrepreneur Award as part of the Celebrate Princeton Innovation event on October 13th.

Key Points: 
  • BORDENTOWN, N.J., Oct. 14, 2022 /PRNewswire/ -- Three founding researchers of Princeton NuEnergy , Dr. Xiaofang Wang, Jerry Xiang, MS, and Dr. Chao Yan have been selected as the recipients of Princeton University's prestigious 2022 Tiger Entrepreneur Award as part of the Celebrate Princeton Innovation event on October 13th.
  • The Tiger Entrepreneur Award is designed to celebrate the value of entrepreneurship across the Princeton community.
  • It is presented to Princeton affiliated individuals or teams who demonstrate success in entrepreneurial endeavors, experience with and commitment to inspiring others through entrepreneurship.
  • Princeton NuEnergy (PNE) is a US-based, innovative clean-tech startup that was spun out ofPrinceton Universityin 2019, launching commercial production in 2022.

Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease

Retrieved on: 
Thursday, July 28, 2022
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Novartis, Lists of diseases, DUB, Gene, Novartis Institute for Tropical Diseases, Doctor of Philosophy, Nutritional science, CFTR, Protein, Cell death, Research, General partnership, Chimera, Cancer, Technology, Deubiquitinating enzyme, Proximity, Berkeley, Associate professor, Industry, Biomedical Research, Health, Howard Hughes Medical Institute, Princeton University Department of Chemistry, UC, Nature Chemical Biology, Science, Therapy, OTUB1, Chemical biology, University, GV, University of California, Berkeley, Cell biology, Drug discovery, Associate, UCSF, WEE1, Patient, Department, Cystic fibrosis, Toxicology, Pharmaceutical industry, Vaccine, Fine chemical, Management, Microscope, Chemistry, Series

Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today launched with $65 million in Series A financing.

Key Points: 
  • Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today launched with $65 million in Series A financing.
  • Many diseases, including cancer and monogenic diseases, are often caused by specific proteins that are abnormally degraded and lost from the cell.
  • In cancer, protective tumor suppressors are aberrantly destroyed, allowing cancer cells to circumvent cell death, thus promoting unobstructed cell proliferation.
  • Vicinitas Therapeutics is a biotechnology company focused on targeted protein stabilizers known as Deubiquituinase Targeting Chimeras (DUBTACs).

DIII-D National Fusion Facility Adds Capability to Rapidly Test Key Fusion Science

Retrieved on: 
Tuesday, July 26, 2022
CA, Copper, University, GLOBE, Human, PPPL, Princeton University, Research, Field line, List of IEEE publications, Solution, Medicine, Nuclear energy, Behavior, United States Department of Energy, General Atomics, Physics, Technology, Princeton University Department of Chemistry, Plant, Heart, Laboratory, Plasma, Electron, Princeton Plasma Physics Laboratory, U.S. Department of Defense Strategy for Operating in Cyberspace, Lithium, Transformer, Medical imaging, Energy, DIII-D, Science

Called a Toroidal Field Reversing Switch (TFRS), this quick-change function is unique to DIII-D and illustrates the facilitys value and flexibility for fusion science.

Key Points: 
  • Called a Toroidal Field Reversing Switch (TFRS), this quick-change function is unique to DIII-D and illustrates the facilitys value and flexibility for fusion science.
  • DIII-D is the largest magnetic fusion research user facility in the United States and is operated by General Atomics for the U.S. Department of Energy Office of Science.
  • The heart of the facility is a tokamak that uses powerful electromagnets to produce a toroidal (doughnut-shaped) magnetic bottle for confining a fusion plasma.
  • DIII-D is the largest magnetic fusion research facility in the U.S. and has been the site of numerous pioneering contributions to the development of fusion energy science.

David Crane Joins Source Global’s Board of Directors

Retrieved on: 
Monday, July 11, 2022
Other Energy, Utilities, Hardware, Other Natural Resources, Sustainability, Energy, Technology, Agriculture, Agritech, Natural Resources, Environment, Green Technology, Other Technology, LinkedIn, NRG Energy, Instagram, Leadership, Great power, CEO, Director, Princeton University, Fourth Estate Public Benefit Corporation, Climate, International relations, Crane, Founder CEO, Engie Energy International, Carbon, Lehman Brothers, Atmosphere, Water, NRG, Princeton School of Public and International Affairs, Technology, Drinking water, PBC, Princeton University Department of Chemistry, School, Non-governmental organization, Twitter, Growth, Hospital, Harvard Law School, Board, Board of directors, Renewable energy, Facebook

SOURCE Global, PBC, innovator of disruptive renewable drinking water technology, has appointed David Crane to its Board of Directors.

Key Points: 
  • SOURCE Global, PBC, innovator of disruptive renewable drinking water technology, has appointed David Crane to its Board of Directors.
  • David shares our vision of a sustainable, equitable world and is a pioneer in the truest sense of the word.
  • Its an honor to welcome him to the Board of Directors, said Cody Friesen, founder & CEO, SOURCE Global.
  • Crane was president and CEO of NRG Energy from 2003 to 2015, the leading integrated power company in the U.S.

Stephen W. Dailey, MD, FAMSSM is recognized by Continental Who's Who

Retrieved on: 
Tuesday, June 28, 2022
Princeton University Department of Chemistry, Miami University, Medical degree, Attending physician, UC, Patient, Harry Oppenheimer Fellowship Award, Continental, ABEM, Society, University, American Medical Society for Sports Medicine, American Board of Emergency Medicine, Head Injuries, Medical specialty, Academic Emergency Medicine, American Board of Medical Specialties, Fellow of the American College of Emergency Physicians, Faculty, OH, Ohio University, Physician, Society for Academic Emergency Medicine, Family, American College, Emergency medicine, Fellow, American Board of Commissioners for Foreign Missions, MD, Multimedia, Education, Volunteering, Dentistry, Medicine, Science, Zoology, Sports medicine

A board-certified and fellowship-trained specialist, Dr. Dailey has more than 30 years of experience in his field.

Key Points: 
  • A board-certified and fellowship-trained specialist, Dr. Dailey has more than 30 years of experience in his field.
  • He is an Ohio-based Emergency Medicine Physician in practice with UC Sports Physicians, providing non-surgical therapies to treat orthopedic muscular-skeletal injuries.
  • In addition to seeing patients at the practice, Dr. Dailey also serves as an Assistant Professor with UC Health Orthopedics & Sports Medicine and Emergency Medicine.
  • The ABEM is one of 24 medical specialty certification boards recognized by the American Board of Medical Specialties.

SunHydrogen Engages Elite Scientist Dr. Arthur J. Nozik as Scientific Adviser

Retrieved on: 
Tuesday, May 10, 2022
National Renewable Energy Laboratory, Quantum, University of Colorado Colorado Springs, Department, Private Securities Litigation Reform Act, Solar energy, Seawater, University, Carbon, Argonne–Northwestern Solar Energy Research Center, Water, GLOBE, Electronics, Company, Principal Scientific Adviser to the Government of India, Nanostructure, Hydrogen, Nanoparticle, CA, Sunlight, Chemical engineering, Natural gas, OTC, Coal, Book, Knowledge, American Cyanamid, Electricity, Relaxation, Science, Samsung, Allied Corporation, Cornell University, Technology, Princeton University Department of Chemistry, Solution, NREL, Yale University, Renewable energy

in Chemical Engineering from Cornell University in 1959 and his Ph.D. in Physical Chemistry from Yale University in 1967.

Key Points: 
  • in Chemical Engineering from Cornell University in 1959 and his Ph.D. in Physical Chemistry from Yale University in 1967.
  • From the start of my career, I have been extremely interested in and focused on exactly what SunHydrogen is doing, said Dr. Nozik.
  • Dr. Nozik brings an immense wealth of knowledge to our team, said SunHydrogen CEO Tim Young.
  • SunHydrogen is developing a breakthrough, low-cost technology to make renewable hydrogen using sunlight and any source of water, including seawater and wastewater.

Kennan Salinero, Co-Founder and Executive Director of ReImagine Science, Speaks to the NextNow Community

Retrieved on: 
Saturday, April 2, 2022
Organization, Adobe, Institute of Noetic Sciences, STEM, IBM, Multimedia, Research, Faculty, Genomics, View, Noetics, Georgetown University, Institute, IEEE, Samsung, Cell biology, Policy, Department, Princeton University Department of Chemistry, Education, University of California, Berkeley, Public relations, Management, Google, Science

NextNow was founded over 20 years ago by a group of technologists, humanitarians, and futurists.

Key Points: 
  • NextNow was founded over 20 years ago by a group of technologists, humanitarians, and futurists.
  • Since that time, NextNow has grown into a global, multidisciplinary network of people devoted to maintaining focus on humanity amid accelerating technological change.
  • The speaker for this NextNow talk will be Kennan Salinero, co-founder and executive director of ReImagine Science, a non-profit on a mission to reimagine how we 'do' science in the United States.
  • ReImagine Science is a 501(c)3 organization founded in 2008 to fundamentally change the way we 'do' science in the United States.

Altesa BioSciences Announces Scientific Advisory Board

Retrieved on: 
Monday, February 28, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Princeton University Department of Chemistry, RNA, Drug development, COVID-19, Virology, GA, Gilead Sciences, Distinguishing, Coronavirus Scientific Advisory Board (Turkey), Chronic obstructive pulmonary disease, Department, HIV, Division, Therapy, Rhinovirus, Partnership, Board, University of North Carolina, University, Emory University School of Medicine, Safety, MS, Critical Care Medicine (journal), Drug discovery, Pulmonology, Collaboration, CEO, Emory University, Director, Chapel Hill, DSMB, Critical care, SAB, Neurosurgery, DRIVE, International Advisory and Monitoring Board, Patient, Doctor of Philosophy, Orthornavirae, Physician, NIH, Infection, FDA, COPD, Emtricitabine, Pharmaceutical industry, Pediatrics, Pharmacology, Medicine, Vaxart, Microbiology, Molnupiravir, Health, Enterovirus, MD

Altesa BioSciences, Inc., a clinical-stage biopharmaceutical company developing and commercializing novel anti-viral drugs against common respiratory viruses and global viral threats, today announced the inaugural members of its Scientific Advisory Board (SAB).

Key Points: 
  • Altesa BioSciences, Inc., a clinical-stage biopharmaceutical company developing and commercializing novel anti-viral drugs against common respiratory viruses and global viral threats, today announced the inaugural members of its Scientific Advisory Board (SAB).
  • Altesa BioSciences, Inc is a biopharmaceutical company based in Atlanta, GA focused on developing antivirals to addresses diseases of global importance.
  • In July 2021, Altesa in-licensed Vapendavir, a Phase 2 antiviral broadly active against enteroviruses, including rhinovirus, from Vaxart.
  • Altesa intends to progress Vapendavir into Phase 2b trial in the coming months for treatment of rhinovirus in at-risk populations.

Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform

Retrieved on: 
Wednesday, February 16, 2022
MSD, Merck & Co., Merck, Department, Doctor of Philosophy, Therapy, Technology, NJ, Protein, University, Princeton University Department of Chemistry, Research, Drug discovery, MBA, Cytoplasm, Pharmaceutical industry, Generic drug, Fine chemical, Curve

Simon Kerry, PhD, MBA, Chief Executive Officer of Curve, said: "This collaboration is a major milestone for Curve and an important endorsement of our ground-breaking drug discovery platform.

Key Points: 
  • Simon Kerry, PhD, MBA, Chief Executive Officer of Curve, said: "This collaboration is a major milestone for Curve and an important endorsement of our ground-breaking drug discovery platform.
  • Curve's novel, proprietary platform enables the direct discovery of biologically active molecules against targets that have been difficult to address using conventional drug discovery methods.
  • Curve is pioneering a game-changing, functional, drug discovery engine to generate higher quality hits and leads with the aim of discovering first-in-class therapeutics.
  • Curve's platform enables the discovery of biologically active molecules against targets that have evaded conventional drug discovery techniques.